NCT00963547 2024-06-04
MK-2206-015
Merck Sharp & Dohme LLC
Phase 1 Terminated
Clinical Trials
7 trialsNCT00848718 2019-11-12
MK-2206-003
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00670488 2019-04-01
MK-2206-002
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01243762 2018-08-16
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01021748 2018-08-07
A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01071018 2015-09-07
A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01295632 2015-08-27
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
Merck Sharp & Dohme LLC
Phase 1 Completed